Nautilus Biotechnology opened lower at $2.88, compared with its previous close of $3.14. In the last trading session, the stock traded between $2.64 and $3.08. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Nautilus Biotechnology is now worth
$ 50.28
resulting in a loss of
$ 49.72 (49.72%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.46 (-14.49%)
Day High
$3.08
Day Low
$2.64
Day Open
$2.88
Prev Close
$3.14
Volume
57,61,259
1W Return
3.07%
1M Return
95.84%
3M Return
159.42%
6M Return
7.40%
1Y Return
90.43%
Fundamentals
Market Cap ($ Mn)
342
PE Ratio
-
PB Ratio
0.86
PEG Ratio
-
ROE
-32.40%
ROCE
-32.31%
EPS (TTM)
$-0.12
Investment Returns
1 Week
3.07%
1 Month
95.84%
3 Months
159.42%
6 Months
7.40%
9 Months
38.40%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
9Sep
Leerink initiates Nautilus Biotech coverage with $4 price target
Leerink Partners initiates coverage on Nautilus Biotechnology. Analyst Puneet Souda assigns an Outperform rating. Price target set at $4 per share.
1mo ago
4Sep
Nautilus validates tau proteoform assay in Nature Methods publication
Nautilus published in *Nature Methods* validating Iterative Mapping for tau proteoforms. Assay resolved 130 proteoform groups with median CV below 5.5%. Method detected proteoforms at 0.1% of sample concentration. Company targets roughly 20 proteoform assays by mid-2028.
1mo ago
28Jul
Nautilus Biotechnology Q2 Results: EPS beats estimates by 21%
Nautilus Biotechnology delivered a better-than-expected Q2 performance, with EPS of $(0.11) beating the $(0.14) estimate by 21.43%. The company also saw a year-over-year improvement in losses, which narrowed by 8.33% from $(0.12). Total sales for the quarter were $190,000.
3mo ago
8Jul
Nautilus Biotechnology to announce Q2 2026 results on July 28
Nautilus Biotechnology, Inc. will release its Q2 2026 financial results on July 28, 2026, prior to market open. A conference call is scheduled for 8:30 a.m. ET to discuss the results and business outlook. The webcast will be available on the company's website.
